XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 148.9 $ 117.0
Marketable investment securities 27.2 33.7
Prepaid expenses 13.9 11.7
Inventory 24.6 27.1
Trade accounts receivable 94.1 89.5
Prepaid taxes 18.1 108.4
Other receivables 2.4 2.0
Total current assets 329.2 389.4
Property, plant and equipment, net 45.1 40.7
Operating lease right-of-use assets 58.9 59.7
Long-term marketable investment securities 11.9 21.0
Intangibles, net 559.9 576.5
Goodwill 328.3 329.2
Other assets 3.6 2.3
Total assets 1,336.9 1,418.8
Current liabilities:    
Accounts payable 20.8 20.5
Accrued liabilities 83.1 79.1
Current maturities of operating lease liabilities 14.0 13.6
Deferred revenue 31.1 32.7
Total current liabilities 149.0 145.9
Unrecognized tax benefits 30.8 30.5
Long-term deferred taxes 59.2 71.3
Long-term debt 154.0 224.8
Noncurrent operating lease liabilities 49.4 50.6
Other long-term liabilities 19.3 14.7
Total liabilities 461.7 537.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 76.7 and 75.4 shares outstanding at March 31, 2021 and December 31, 2020, respectively 0.8 0.8
Additional paid-in capital 1,144.5 1,109.5
Accumulated other comprehensive loss (3.6) (2.3)
Accumulated deficit (266.5) (227.0)
Total Myriad Genetics, Inc. stockholders’ equity 875.2 881.0
Non-controlling interest 0.0 0.0
Total stockholders' equity 875.2 881.0
Total liabilities and stockholders’ equity $ 1,336.9 $ 1,418.8